Site Map Press Room Careers
Financial
Financial Results
Financial Highlights
Annual Reports
Business Drivers
Investors
Contact Person
Frequently Asked Questions
 Financial Results
Audited Financial Results for the Year ended 31st March, 2003
  (Rs.in Mio)
Particulars Unaudited Results For Audited Results For Consolidated Results
Nine Months Ended Three Months Ended The Year Ended For The Year Ended
31.12.2002 31.03.2003 31.03.2002 31.03.2003 31.03.2002 31.03.2003 31.03.2002
Net Sales/Income from Operations 8536.4 3367.4 3190.5 11903.8 10377.2 13365.8 11635.5
Other Income 68.2 172.3 27.3 240.5 146.8 255.8 179.4
Total income 8604.6 3539.7 3217.8 12144.3 10524.0 13621.6 11814.9
Expenditure

0.0

            
a. (Increase)/Decrease in Stock in Trade (204.1) (114.9) 178.5 (319.0) 209.3 (431.3) 672.7
b. Consumption of Raw Material 5670.7 1877.0 2009.6 7547.7 6671.7 8724.3 7274.0
c. Staff Cost 188.4 146.8 69.9 335.2 251.7 434.4 267.0
d. Other Expenditure 1721.6 800.2 580.3 2521.8 2020.9 2887.4 2154.6
Total expenditure 7376.6 2709.1 2838.3 10085.7 9153.6 11614.8 10368.3
Profit before depreciation, interest & tax 1228.0 830.6 379.5 2058.6 1370.4 2006.8 1446.6
Interest 312.0 113.9 109.4 425.9 423.9 478.1 453.7
Depreciation 128.7 103.1 39.8 231.8 158.1 291.2 159.4
Profit before extra-ordinary item & taxation 787.3 613.6 230.3 1400.9 788.4 1237.6 833.5
Add: Extra-ordinary item - - 100.0 - 100.0 - 100.0
Profit after extra ordinary item & before taxation 787.3 613.6 330.3 1400.9 888.4 1237.6 933.5
Provision for Taxation              
a. Current Tax 165.0 88.0 66.7 253.0 153.7 255.5 155.5
b. Deferred Tax 54.6 57.5 25.9 112.1 37.9 108.3 35.4
c. Tax adjustments of previous years - 4.4 11.7 4.4 11.7 4.4 11.7
Net Profit 567.7 463.7 226.0 1031.4 685.1 869.4 730.9
Paid-up Equity Share Capital (Face value Rs. 10 per share) 232.5 232.5 206.7 232.5 206.7    
Reserves excluding Revaluation Reserve       5101.4 3406.9 4720.0 3352.8
Basic Earnings per share (Rs.) (not annualised) 25.21 19.95 11.16 45.46 33.89 38.29 36.11
Diluted Earnings per share (Rs.) 25.21 19.95 11.16 45.46 33.89 38.29 36.11
Aggregate of non-promoters Shareholding              
a. Number of Shares       8930473 6978167    
b. Percentage of Shareholding       38.41 33.76    
 
Segment wise Revenue, Results and Capital employed
 

(Rs. in Mio)

Particulars Unaudited Results For Audited Results For Consolidated Results
Nine Months Ended Three Months Ended The Year Ended For The Year Ended
31.12.2002 31.03.2003 31.03.2002 31.03.2003 31.03.2002 31.03.2003 31.03.2002
1. Segment Revenue              
a . Bulk Drugs & Drug Intermediaries 8334.1 3845.0 4074.5 12179.1 10855.9 12478.8 11092.4
b. Formulation 477.2 165.3 411.2 642.5 1061.7 642.6 923.9
c. Research & Development - - - - - - -
d. Others - - - - - 469.7 623.9
Total 8811.3 4010.3 4485.7 12821.6 11917.6 13591.1 12640.1
Less: Inter segment revenue 254.7 604.6 1193.3 859.3 1433.0 859.3 1483.9
Net Sales/Income from operation 8556.6 3405.7 3292.4 11962.3 10484.0 12731.8 11156.3
2. Segment Results Profit(+) / Loss(-) before tax and interest              
a .  Bulk Drugs & Drug Intermediaries 1190.4 661.9 573.8 1852.3 1444.6 2014.5 1481.8
b. Formulation 67.7 29.4 211.6 97.1 227.8 (37.6) (28.0)
c. Research & Development (83.9) (45.5) (11.4) (129.4) (60.5) (129.5) (70.2)
d. Others - - - - - (138.3) 11.6
Total 1174.2 645.8 774.0 1820.0 1611.9 1709.2 1395.3
Less:  (I) Interest (Net) 269.0 112.8 100.1 381.8 392.5 447.7 419.9
(ii) Other un-allocable expenditure net of unallocable income 117.9 (80.6) 343.4 37.3 330.9 24.0 41.9
Total Profit before tax 787.3 613.6 330.5 1400.9 888.5 1237.6 933.4
3. Capital Employed              
a .  Bulk Drugs & Drug Intermediaries 5134.6 7331.6 3870.9 7331.6 3870.9 9822.9 5681.8
b.  Formulation 1312.9 1463.3 1180.0 1463.3 1180.0 1636.4 1200.7
c.  Research & Development 211.3 256.1 173.9 256.1 173.9 256.1 174.6
d. Others - - - - - 244.4 254.5
Total 6658.8 9051.0 5224.8 9051.0 5224.8 11959.8 7311.6
Notes:
1. The above audited Quarterly Results have been taken on record by the Board of Directors at its meeting held on 30.06.2003.
2. In terms of Accounting Standard - 17, the revenue, results and capital employed have been given segment wise.
3. The Board recommends dividend @35% on pro rata basis on the equity share capital of the Company subject to members approval.
4. The Quarterly Results for the IV quarter and year 2002-03 are not comparable with those of the previous quarter and year results as they include the Quarterly Results of Ranit Pharma Ltd and Calac Pvt. Ltd which were amalgamated with the Company with effect from 1st April 2002.
5. The consolidated Quarterly Results include the results of subsidiary companies and joint venture companies as per Accounting Standard 21& 27.
6. The consolidated Quarterly Results for the year 2002-2003 are not comparable with those of the previous year as investmetns in the joint venture compan during the previous year were accounted in line with AS - 13 'Accounting for Investments'.
7. The Board has approved the delisting of Company's equity shares from the Ahmedabad and Madras Stock Exchanges subject to members and other necessary approvals. However, they continue to be listed on Hyderabad, Bomaby and National Stock Exchanges.
8. Figures have been regrouped wherever necessary.
    For and on behalf of the Board
Place: Hyderabad    K.Nityananda Reddy
Date : 30.06.2003   Managing Director
Site Map Press Room Careers